HSD3 Real-World Outcomes and Practice Patterns for Long-Acting Injectable Vs. Oral Antipsychotic Agents Among Hospitalized Patients with Schizophrenia in the United States

J.M Kane,J.M Rubio,J Casciano,Z Dotiwala,R Hansen,K.R Franzenburg,M Philbin,S Thompson

doi:10.1016/j.jval.2023.03.1312

HSD3 Real-World Outcomes and Practice Patterns for Long-Acting Injectable Vs. Oral Antipsychotic Agents Among Hospitalized Patients with Schizophrenia in the United States

J.M Kane, J.M Rubio + Show 6 more

https://doi.org/10.1016/j.jval.2023.03.1312

Copy DOI

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Publication Date: Jun 1, 2023

Affiliation: Zucker Hillside Hospital, Teva Pharmaceuticals (United States)

#Long-acting Injectable Antipsychotics #Differences In Re-hospitalization Rates + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Treatment options for schizophrenia include oral antipsychotics (OAs) and long-acting injectable antipsychotics (LAIs). Previous studies have reported that patients taking LAIs have lower relapse/re-hospitalization risks; however, more patients are prescribed OAs than LAIs. Here, we explore differences in re-hospitalization rates after schizophrenia-related hospitalization for patients prescribed LAIs vs OAs at discharge.

Full Text